Subsequent mechanistic studies showed that LSD1 inhibitors act by inhibiting ASCL1, through silencing of INSM1 or derepression of NOTCH1, as well as efficacy in chemoresistant PDXs of SCLC [222,223]. This evidence concerns the gene KDM1A and small cell lung carcinoma.